1:04 PM
 | 
Jan 12, 2018
 |  BC Week In Review  |  Company News  |  Deals

Sanofi, Regeneron expand 2015 immuno-oncology agreement

Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) expanded a 2015 immuno-oncology deal to increase and accelerate investment in the clinical development of anti-PD-1 mAb cemiplimab (REGN2810, SAR439684) for cancer and Dupixent dupilumab (REGN668, SAR231893) for allergic diseases.

In 2015, the partners entered a five-year deal to jointly develop and commercialize immuno-oncology candidates including cemiplimab and a pipeline of preclinical monoclonal and bi-specific antibodies. Under...

Read the full 305 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >